Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement “as monotherapy for the first-line treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)”.
Clinical Benefit
| Low |
The Committee deems that the clinical benefit of RETSEVMO (selpercatinib) 40 mg and 80 mg hard capsules is substantial in the indication “as monotherapy for the first-line treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)”.
|
Clinical Added Value
| no clinical added value |
As first-line treatment, considering:
- demonstration of a superiority of RETSEVMO (selpercatinib) compared to cabozantinib or vandetanib in terms of progression-free survival assessed by an independent review committee (HR = 0.280; CI95% [0.165; 0.475], p<0.0001), in a phase 3, randomised, open-label trial (LIBRETTO-531);
- a safety judged to be favourable;
- management considered to be similar for adults and adolescents. Since the studies (LIBRETTO-001 and LIBRETTO-531) only included three adolescents, the efficacy data in adults were accepted as being extrapolable to adolescents 12 years and older;
and despite:
- the lack of evidence of an improvement in overall survival (non-ranked secondary endpoint)
following the interim analysis, in a context of advanced disease with an unfavourable prognosis;
- the absence of any formal conclusion that can be drawn based on the exploratory quality of life findings;
- results available with a short follow-up period (median follow-up of 1 year on the interim analysis, which became the primary analysis);
the Committee deems that RETSEVMO (selpercatinib) provides a minor clinical added value (CAV IV) compared to vandetanib or cabozantinib in the first-line treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).
|
eNq9mE1z2jAQhu/8Co8PvdkOX2nSGjItTVpmkiklYdrpJSPsJYgayVlJfPTXV8akIR150giUI5a8u9pdPfvi+Gw1z7wFoKCcdfx6eOR7wBKeUnbX8Uc3F8GJf9atxTOyII/bGnpfWK/7XpIRITp+sRqOgTAR/ri6/AT6fUC/W/NiPp5BIp/sU5Jm4RciplckL/Z48YLT1JuDnPK04+dKbp56sZCoo+guOf4SOUkgjrZPdldnt63d53FUGPsPq0oAXhJ2ZzQKzMpmohCByR6RcMdxXRFv08o2FUMQXGECAyKnA+QLmkJqdDEhmQArJ5Nleg24yEAWTozGo1kyF1bGyYyshnDfNwf9Qa/25EoGR0H97WmzftxottrtxlsrV7iTKnMV9CGi/LapHbSOGxGwCEEKWMx5ICDLARMiKaPjQE7XqF0FCWEJYCATy+INOEqSOSobFb2nnefID8L9s+2RUpFnZB3ORG6bKoJELwNqPrg7SHGCG9TEynTO/rHPVJZFL4x6tOWJo4gLXPW4YrICKxdD20T0OJOwqq6oHQnlatuLFMThzP7mzDwFBmqc0cSWeZpKCoQcDfvVyHtVWnwkAkboDhffKUv5UhweQ7tldxR9viGp0WiOaf22cXpyXG+3rW/ZT91jFTPqXCHPIdKAomIf7vTZhO9LHN22ZlMPTft6/bqRUjwhGVSIqcCSTrpRH7Sfs6vg7pqVC0ajn89vbPvnmwJcX29+Gk3TtPO38nbodjEPdLc+F3h5r4vgj9onp83WGzLP3z+o9I6lIi+NOhHkCs0QmkqZi3dRtFwuwykRgSA6n+EE95giZ8bcHCI/GtmP5Xb3p8KJxig1V4lrR6GPyzn8sjrb3uznVMi+ynr7/lbBG31IVLBHLcoh4AzV/fPD0/9RVjsLe/CEQe7cbCSwRghnrpSXGpvJvde80XVlF6gB8XUyoRUfeSr7Mo7KD0zdWhwVH5e6tT+F+DRD
wpWYH4n6gts14kAU